Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism

J Immunol. 2007 Jul 15;179(2):812-8. doi: 10.4049/jimmunol.179.2.812.

Abstract

Dendritic cells (DCs) are well known for their capacity to induce adaptive antitumor immune response through Ag presentation and tumor-specific T cell activation. Recent findings reveal that besides this role, DCs may display additional antitumor effects. In this study, we provide evidence that LPS- or IFN-gamma-activated rat bone marrow-derived dendritic cells (BMDCs) display killing properties against tumor cells. These cytotoxic BMDCs exhibit a mature DC phenotype, produce high amounts of IL-12, IL-6, and TNF-alpha, and retain their phagocytic properties. BMDC-mediated tumor cell killing requires cell-cell contact and depends on NO production, but not on perforin/granzyme or on death receptors. Furthermore, dead tumor cells do not exhibit characteristics of apoptosis. Thus, intratumoral LPS injections induce an increase of inducible NO synthase expression in tumor-infiltrating DCs associated with a significant arrest of tumor growth. Altogether, these results suggest that LPS-activated BMDCs represent powerful tumoricidal cells which enforce their potential as anticancer cellular vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Blotting, Western
  • Bone Marrow Cells / immunology
  • Cell Death / physiology*
  • Cell Line, Tumor
  • Cytotoxicity, Immunologic*
  • Dendritic Cells / drug effects
  • Dendritic Cells / metabolism*
  • Flow Cytometry
  • Humans
  • Lipopolysaccharides / pharmacology
  • Neoplasms / immunology*
  • Nitric Oxide / metabolism*
  • Rats

Substances

  • Adjuvants, Immunologic
  • Lipopolysaccharides
  • Nitric Oxide